article Open AccessTop 1% cited
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
New England Journal of Medicine · 2020 · Vol. 383(27) · pp. 2603–2615
Fernando P. Polack✉(SUNY Upstate Medical University)Stephen J. Thomas(Johns Hopkins University)Nicholas Kitchin(Institut de Recherche Vaccinale)Judith Absalon(Johns Hopkins University)Alejandra Gurtman(Institut de Recherche Vaccinale)Stephen Lockhart(Institut de Recherche Vaccinale)John L. Perez(Johns Hopkins University)Gonzalo Pérez Marc(SUNY Upstate Medical University)Edson Duarte Moreira(SUNY Upstate Medical University)Cristiano A. F. Zerbini(Institut de Recherche Vaccinale)Ruth Bailey(Johns Hopkins University)Kena A. Swanson(Johns Hopkins University)Satrajit Roychoudhury(SUNY Upstate Medical University)Kenneth Koury(SUNY Upstate Medical University)Ping Li(SUNY Upstate Medical University)Warren V. Kalina(SUNY Upstate Medical University)David Cooper(SUNY Upstate Medical University)Robert W. Frenck(Institut de Recherche Vaccinale)Laura L Hammitt(Johns Hopkins University)Özlem Türeci(Institut de Recherche Vaccinale)Haylene Nell(Johns Hopkins University)Axel Schaefer(SUNY Upstate Medical University)Serhat Ünal(Institut de Recherche Vaccinale)Dina B Tresnan(Institut de Recherche Vaccinale)Susan Mather(Institut de Recherche Vaccinale)Philip R. Dormitzer(Johns Hopkins University)Uğur Şahin(SUNY Upstate Medical University)Kathrin U. Jansen(SUNY Upstate Medical University)William C. Gruber(SUNY Upstate Medical University)
Abstract
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
SARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyViral Infections and Immunology ResearchCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyBusinessMedicineOutbreakInternal medicineInfectious disease (medical specialty)
MeSH terms
COVID-19SARS-CoV-2COVID-19 VaccinesmRNA VaccinesBNT162 VaccineAdolescentAdultAgedFatigueFemaleHeadacheHumansImmunization, SecondaryMaleMiddle Aged
Funding
- Pfizer
Citations
15,281
FWCI
311.19
field-weighted impact
References
8
Percentile
100%
vs. same field & year
Citations per year
Cited by
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
New England Journal of Medicine · 2020 · 10,528 citations
Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19
Cells · 2021 · 446 citations
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
BMJ · 2021 · 1,387 citations
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
The Lancet Infectious Diseases · 2021 · 1,078 citations
mRNA vaccines manufacturing: Challenges and bottlenecks
Vaccine · 2021 · 488 citations
Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases
Journal of the American Academy of Dermatology · 2021 · 805 citations
Mechanisms of SARS-CoV-2 entry into cells
Nature Reviews Molecular Cell Biology · 2021 · 3,127 citations
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability
International Journal of Pharmaceutics · 2021 · 1,403 citations
References
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
Journal of Controlled Release · 2015 · 999 citations
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Science · 2020 · 9,712 citations
The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application
Annals of Internal Medicine · 2020 · 6,567 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.